Anastrozole

Generic Name
Anastrozole
Brand Names
Arimidex
Drug Type
Small Molecule
Chemical Formula
C17H19N5
CAS Number
120511-73-1
Unique Ingredient Identifier
2Z07MYW1AZ
Background

Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...

Indication

Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...

Associated Conditions
Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: anastrozole
Procedure: adjuvant therapy
First Posted Date
2005-10-27
Last Posted Date
2013-03-19
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
54
Registration Number
NCT00244959
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

First Posted Date
2005-09-22
Last Posted Date
2014-05-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT00217399
Locations
🇺🇸

Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

Phase 2
Withdrawn
Conditions
Breast Cancer
First Posted Date
2005-09-22
Last Posted Date
2013-01-03
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00217659
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States

🇺🇸

Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States

and more 53 locations

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Phase 3
Completed
Conditions
Breast Neoplasms
Interventions
Drug: exemestane
Drug: anastrozole
First Posted Date
2005-09-02
Last Posted Date
2012-01-25
Lead Sponsor
Pfizer
Target Recruit Count
298
Registration Number
NCT00143390
Locations
🇯🇵

Pfizer Investigational Site, Shizuoka, Japan

Anastrozole Administration in Elderly Hypogonadal Men

Phase 2
Completed
Conditions
Hypogonadism
Interventions
Drug: anastrozole
First Posted Date
2005-08-29
Last Posted Date
2022-09-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
88
Registration Number
NCT00136695
Locations
🇺🇸

General Clinical Research Center, Massachusetts General Hospital, Boston, Massachusetts, United States

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Exemestane
First Posted Date
2005-08-10
Last Posted Date
2023-03-06
Lead Sponsor
Spanish Breast Cancer Research Group
Target Recruit Count
103
Registration Number
NCT00128843
Locations
🇪🇸

Ruber Internacional, Madrid, Spain

🇪🇸

H Universitario Miguel Servet, Zaragoza, Spain

🇪🇸

Hospital Donostia, Donostia-San Sebastián, Guipúzcoa, Spain

and more 10 locations

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

Phase 2
Completed
Conditions
Puberty, Precocious
Interventions
Drug: Bicalutamide
Drug: Anastrozole
First Posted Date
2004-10-18
Last Posted Date
2018-06-26
Lead Sponsor
AstraZeneca
Target Recruit Count
14
Registration Number
NCT00094328
Locations
🇬🇧

Research Site, London, United Kingdom

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-08-23
Last Posted Date
2013-05-30
Lead Sponsor
Hackensack Meridian Health
Registration Number
NCT00004906
Locations
🇺🇸

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-08-20
Last Posted Date
2013-05-30
Lead Sponsor
Hackensack Meridian Health
Registration Number
NCT00004900
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

Phase 4
Completed
Conditions
Breast Cancer
Interventions
Drug: Anastrozole
Drug: Risedronate Sodium
First Posted Date
2004-05-06
Last Posted Date
2011-01-26
Lead Sponsor
AstraZeneca
Target Recruit Count
237
Registration Number
NCT00082277
Locations
🇬🇧

Research Site, Luton, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy